Michael Fredericks, MD
Nephrology · Danville, VANPI 1699730341
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,517 of the $7,032 with a category attached, or 78.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 342 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$752
- Ardelyx, Inc.$737
- Travere Therapeutics, Inc.$722
- Vifor Pharma, Inc.$674
- Bayer$530
- Fresenius USA Marketing, Inc.$436
- plus $3K from 25 others
Across 71 payments — averaging $1153.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$81K
- Novo Nordisk AS$500
What the payments were for
- Consulting fees$2253%
- Speaking & faculty fees$5508%
- Travel & lodging$3555%
- Food & beverage$5,51778%
- Education$3185%
- Other$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $752 |
| Ardelyx, Inc. | 18 | $737 |
| Travere Therapeutics, Inc. | 42 | $722 |
| Vifor Pharma, Inc. | 33 | $674 |
| Bayer | 26 | $530 |
| Fresenius USA Marketing, Inc. | 6 | $436 |
| Mallinckrodt Hospital Products Inc. | 24 | $396 |
| Otsuka America Pharmaceutical, Inc. | 21 | $357 |
| Sanofi US Services Inc. | 1 | $350 |
| Daiichi Sankyo Inc. | 35 | $321 |
| Akebia Therapeutics Inc | 19 | $269 |
| OPKO Pharmaceuticals, LLC | 16 | $243 |
| Amgen(2 entities) | 14 | $239 |
| Novo Nordisk | 7 | $211 |
| Boehringer Ingelheim | 6 | $126 |
| GSK | 6 | $97 |
| Accord Healthcare, Inc. | 4 | $75 |
| Aurinia Pharma U.S., Inc. | 4 | $66 |
| Calliditas Therapeutics US Inc. | 3 | $63 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Novartis | 3 | $54 |
| Welch Allyn | 2 | $35 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Baxter Healthcare | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| 180 Medical, Inc. | 1 | $28 |
| Nxstage Medical, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$486
- SOLIQUA 100/33$350
- Veltassa$200
- Kerendia$125
- Ozempic$104
How this compares
$7,032 in reported general payments places this provider in the 85th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 158 | $123,630 |
| JardianceEmpagliflozin | 121 | $99,833 |
| KerendiaFinerenone | 41 | $35,049 |
| VelphoroSucroferric Oxyhydroxide | 13 | $20,349 |
| Lanthanum Carbonate | 13 | $10,817 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,544 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,370 |
| Sevelamer Carbonate | 55 | $4,527 |
| Doxepin Hcl | 11 | $2,207 |
| Nebivolol Hcl | 41 | $1,456 |
| Paricalcitol | 12 | $1,406 |
| Labetalol Hcl | 60 | $1,399 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 60 | $1,354 |
| Spironolactone | 81 | $704 |
| Atorvastatin Calcium | 32 | $624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $752 | $123,630158 claims |
| Boehringer IngelheimJardiance | $126 | $99,833121 claims |
| BayerKerendia | $530 | $35,04941 claims |
| Fresenius USA Marketing, Inc.Velphoro | $436 | $20,34913 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $30 | $61043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 298 nephrology providers in Virginia.
Other nephrology in Danville
- Yao-Foli SekyemaDanville$7K
- Namrita BavejaDanville$4K
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Ramin TolouianNorfolk$115K
- Mahesh KrishnanMc Lean$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.